TY - JOUR
T1 - Genomic alterations during the in situ to invasive ductal breast carcinoma transition shaped by the immune system
AU - Trinh, Anne
AU - Gil Del Alcazar, Carlos R.
AU - Shukla, Sachet A.
AU - Chin, Koei
AU - Chang, Young Hwan
AU - Thibault, Guillaume
AU - Eng, Jennifer
AU - Jovanovic, Bojana
AU - Aldaz, C. Marcelo
AU - Park, So Yeon
AU - Jeong, Joon
AU - Wu, Catherine
AU - Gray, Joe
AU - Polyak, Kornelia
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/4
Y1 - 2021/4
N2 - The drivers of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition are poorly understood. Here, we conducted an integrated genomic, transcriptomic, and whole-slide image analysis to evaluate changes in copy-number profiles, mutational profiles, expression, neoantigen load, and topology in 6 cases of matched pure DCIS and recurrent IDC. We demonstrate through combined copy-number and mutational analysis that recurrent IDC can be genetically related to its pure DCIS despite long latency periods and therapeutic interventions. Immune “hot” and “cold” tumors can arise as early as DCIS and are subtype-specific. Topologic analysis showed a similar degree of pan-leukocyte-tumor mixing in both DCIS and IDC but differ when assessing specific immune subpopulations such as CD4 T cells and CD68 macrophages. Tumor-specific copy-number aberrations in MHC-I presentation machinery and losses in 3p, 4q, and 5p are associated with differences in immune signaling in estrogen receptor (ER)-negative IDC. Common oncogenic hotspot mutations in genes including TP53 and PIK3CA are predicted to be neoantigens yet are paradoxically conserved during the DCIS-to-IDC transition, and are associated with differences in immune signaling. We highlight both tumor and immune-specific changes in the transition of pure DCIS to IDC, including genetic changes in tumor cells that may have a role in modulating immune function and assist in immune escape, driving the transition to IDC.
AB - The drivers of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) transition are poorly understood. Here, we conducted an integrated genomic, transcriptomic, and whole-slide image analysis to evaluate changes in copy-number profiles, mutational profiles, expression, neoantigen load, and topology in 6 cases of matched pure DCIS and recurrent IDC. We demonstrate through combined copy-number and mutational analysis that recurrent IDC can be genetically related to its pure DCIS despite long latency periods and therapeutic interventions. Immune “hot” and “cold” tumors can arise as early as DCIS and are subtype-specific. Topologic analysis showed a similar degree of pan-leukocyte-tumor mixing in both DCIS and IDC but differ when assessing specific immune subpopulations such as CD4 T cells and CD68 macrophages. Tumor-specific copy-number aberrations in MHC-I presentation machinery and losses in 3p, 4q, and 5p are associated with differences in immune signaling in estrogen receptor (ER)-negative IDC. Common oncogenic hotspot mutations in genes including TP53 and PIK3CA are predicted to be neoantigens yet are paradoxically conserved during the DCIS-to-IDC transition, and are associated with differences in immune signaling. We highlight both tumor and immune-specific changes in the transition of pure DCIS to IDC, including genetic changes in tumor cells that may have a role in modulating immune function and assist in immune escape, driving the transition to IDC.
UR - http://www.scopus.com/inward/record.url?scp=85101792509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101792509&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-20-0949
DO - 10.1158/1541-7786.MCR-20-0949
M3 - Article
C2 - 33443130
AN - SCOPUS:85101792509
SN - 1541-7786
VL - 19
SP - 623
EP - 635
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 4
ER -